Protalix Biotherapeutics, Inc. (PLX)
2.52
-0.01
(-0.40%)
USD |
NYAM |
Oct 28, 10:18
Protalix Biotherapeutics Price to Book Value : 2.844 for Oct. 28, 2026
Price to Book Value Chart
Historical Price to Book Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 2.855 |
| October 26, 2026 | 2.798 |
| October 23, 2026 | 2.877 |
| October 22, 2026 | 2.90 |
| October 21, 2026 | 2.90 |
| October 20, 2026 | 2.979 |
| October 19, 2026 | 2.889 |
| October 16, 2026 | 2.956 |
| October 15, 2026 | 3.047 |
| October 14, 2026 | 2.945 |
| October 13, 2026 | 3.103 |
| October 12, 2026 | 3.137 |
| October 09, 2026 | 3.137 |
| October 08, 2026 | 3.047 |
| October 07, 2026 | 3.058 |
| October 06, 2026 | 3.080 |
| October 05, 2026 | 3.058 |
| October 02, 2026 | 3.058 |
| October 01, 2026 | 3.024 |
| September 30, 2026 | 3.114 |
| September 29, 2026 | 3.035 |
| September 28, 2026 | 3.035 |
| September 25, 2026 | 3.069 |
| September 24, 2026 | 3.103 |
| September 23, 2026 | 3.160 |
| Date | Value |
|---|---|
| September 22, 2026 | 3.205 |
| September 21, 2026 | 3.103 |
| September 18, 2026 | 3.035 |
| September 17, 2026 | 3.047 |
| September 16, 2026 | 3.024 |
| September 15, 2026 | 3.002 |
| September 14, 2026 | 3.126 |
| September 11, 2026 | 2.979 |
| September 10, 2026 | 3.080 |
| September 09, 2026 | 3.013 |
| September 08, 2026 | 2.990 |
| September 04, 2026 | 3.013 |
| September 03, 2026 | 2.956 |
| September 02, 2026 | 2.922 |
| September 01, 2026 | 2.922 |
| August 31, 2026 | 2.90 |
| August 28, 2026 | 2.866 |
| August 27, 2026 | 2.945 |
| August 26, 2026 | 2.798 |
| August 25, 2026 | 2.708 |
| August 24, 2026 | 2.719 |
| August 21, 2026 | 2.686 |
| August 20, 2026 | 2.686 |
| August 19, 2026 | 2.652 |
| August 18, 2026 | 2.640 |
Price to Book Ratio Definition
Price to book value is a valuation ratio that is measured by stock price / book value per share. The book value is essentially the tangible accounting value of a firm compared to the market value that is shown.
Price to Book Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price to Book Value Benchmarks
| Altimmune, Inc. | 0.8325 |
| Taysha Gene Therapies, Inc. | 3.545 |
| Humacyte, Inc. | 4.067 |
| Agenus, Inc. | -- |
| Amgen, Inc. | 20.93 |
Price to Book Value Related Metrics
| PE Ratio | 11.10 |
| PS Ratio | 2.554 |
| PEG Ratio | 0.0536 |
| Price to Free Cash Flow | 26.85 |
| Price | 2.52 |
| Earnings Yield | 9.01% |
| Market Cap | 203.04M |
| PEGY Ratio | 0.0536 |
| Operating PE Ratio | 8.841 |
| Normalized PE Ratio | 11.10 |